DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04829903

CompletedPhase NA

Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin

Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin: Results From a Randomized Double Blinded Clinical Trial

Assets

Dulaglutide / Liraglutide

Listed sites

1

Recruiting sites

—

Enrollment

116

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•HbA1c, change•BMI, change•Treatment-emergent AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04829903
Org study IDDULACAI37628

Timeline

Milestones

Study start2020-01-02actual
Primary completion2021-03-29actual
Study first posted2021-04-02actual
Study completion2021-11-20actual
Last update posted2022-03-14actual

Assets

Investigational agents

DulaglutideLiraglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age12 Years
Maximum age19 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 Diabetes Mellitus
•Obese
•Taking metformin
•Male or female

Exclusion criteria

•Non obese
•Not taking metformin
•Taking other injectable diabetic medications

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Glycemic / diabetes
1
Safety / tolerability / PK
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

BMI

Time frame:24 weeks for the duration of the study

BMI, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Glycemic level

Time frame:24 weeks for the duration of the study

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Adverse effects

Time frame:24 weeks for the duration of the study

Treatment-emergent AEs (any)

descriptive, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.